Hepatitis Clinical Trials

Showing 601-620 of 2,113 trials

What is the Anti-HAV Seroprevalence of Travelers >60 Years or Having Lived in a Tropical Country for >5 Years

NCT04638335

Study to determine the proportion of travelers over the age of 60 years and travelers having lived in a tropical country for more than 5 years with anti-HAV antibodies. This will be done through a blood test. The investigators will then proceed with a short statistical analysis.

Hepatitis A

University of Lausanne Hospitals50 participantsStarted Oct 2019

Lausanne, Canton of Vaud, Switzerland

UNKNOWN

Pharmacokinetics of Sofosbuvir/Daclatasvir in HCV-infected Lactating Women

NCT04852614

This is a prospective, observational, open-label, pharmacokinetic study will evaluate PK of SOF/DAC in lactating HCV-infected females at weaning or women who voluntarily decided to forego breastfeeding to initiate HCV infection treatment. Therefore, drug concentrations can be determined in maternal plasma and milk without risk to the children. HCV infected women at weaning after various durations of breastfeeding and HCV infected women who wish to initiate treatment immediately after delivery and forego breastfeeding will be recruited to start treatment under the guidance of their physician with SOF/DAC to determine M/P ratios of each of SOF, GS-331007 and DAC.

Hepatitis C Virus Infection

Ain Shams University10 participantsStarted Dec 2020

Cairo, Non-US, Egypt

COMPLETEDPhase 3

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

NCT02634008

An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently acquired hepatitis C virus infection with or without HIV co-infection.

Hepatitis C, Acute

Kirby Institute83 participantsStarted Jun 2016

Sydney, New South Wales, Australia • Adelaide, South Australia, Australia • Melbourne, Victoria, Australia +8 more locations

What is the Anti-HAV Seroprevalence of Travelers >60 Years or Having Lived in a Tropical Country for >5 Years

Pharmacokinetics of Sofosbuvir/Daclatasvir in HCV-infected Lactating Women

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

Related Searches

Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy

A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH

Efficacy and Safety of G-CSF in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid

Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients

Atorvastatin Use and Portal Hypertension in Patients With Hepatitis B Virus-related Liver Cirrhosis: A Randomized Controlled Trial

Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children

Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)

Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera

Cameroon HepB Birth Dose Feasibility Pilot

A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy

Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects

Demonstration Project on Health Care Worker Protection Against Hepatitis B in Kalulushi District

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2803 in Healthy Subjects

Study on Clinical Program Optimization of Inactive Hepatitis B Surface Antigen (HBsAg) Carriers (IHCs)